< Back to the team

P. Bravetti

Chief Executive Officer

Medical & Marketing expert
Skills in Immuno-oncology : pharma product launches worldwide

Paul Bravetti (PharmD, HEC Paris) is specialized in medical oncology and brings a wealth of experience from his international career at Roche, Servier, and Takeda Oncology, leading teams in Medical, Marketing, and Commercial functions.

Paul has previously managed successful product launches in immuno-oncology including melanoma, lung cancer and bio-molecular diagnosis across EU and Asia.

Linkedin-in

INCREASE IMMUNOGENICITY

Brenus’ manufacturing process overpasses the lack of immunogenicity & educates the immune system  with visible and multi-specific targets

More about Haptenization & STC immunogenicity
Back to the page

REPRESENT HETEROGENEITY OF THE TARGETED INDICATION

Selection criteria of starting material (Allogeneic tumor cell lines)

  • Representative oncogenic drivers (TP53,BRAF,KRAS,…)
  • Cold & hot tumor cell lines
  • Resistances capacities (metabolic ; chemical & physical)
Back to the page

Increase antigenicity

Brenus’ manufacturing process overpasses the lack of antigenicity & educates the immune system  with a broad & higher quality range of tumor antigens

More about STC Antigenicity
Back to the page